Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T50773
(Former ID: TTDI03155)
|
|||||
| Target Name |
Dipeptidyl-peptidase 7 (DPP7)
|
|||||
| Synonyms |
Quiescent cell proline dipeptidase; QPP; Dipeptidyl peptidase II; Dipeptidyl peptidase 7; Dipeptidyl peptidase 2; Dipeptidyl aminopeptidase II; DPP2; DPP II
Click to Show/Hide
|
|||||
| Gene Name |
DPP7
|
|||||
| Target Type |
Patented-recorded target
|
[1] | ||||
| Function |
Plays an important role in the degradation of some oligopeptides.
Click to Show/Hide
|
|||||
| UniProt ID | ||||||
| EC Number |
EC 3.4.14.2
|
|||||
| Sequence |
MGSAPWAPVLLLALGLRGLQAGARRAPDPGFQERFFQQRLDHFNFERFGNKTFPQRFLVS
DRFWVRGEGPIFFYTGNEGDVWAFANNSAFVAELAAERGALLVFAEHRYYGKSLPFGAQS TQRGHTELLTVEQALADFAELLRALRRDLGAQDAPAIAFGGSYGGMLSAYLRMKYPHLVA GALAASAPVLAVAGLGDSNQFFRDVTADFEGQSPKCTQGVREAFRQIKDLFLQGAYDTVR WEFGTCQPLSDEKDLTQLFMFARNAFTVLAMMDYPYPTDFLGPLPANPVKVGCDRLLSEA QRITGLRALAGLVYNASGSEHCYDIYRLYHSCADPTGCGTGPDARAWDYQACTEINLTFA SNNVTDMFPDLPFTDELRQRYCLDTWGVWPRPDWLLTSFWGGDLRAASNIIFSNGNLDPW AGGGIRRNLSASVIAVTIQGGAHHLDLRASHPEDPASVVEARKLEATIIGEWVKAARREQ QPALRGGPRLSL Click to Show/Hide
|
|||||
| 3D Structure | Click to Show 3D Structure of This Target | PDB | ||||
| Cell-based Target Expression Variations | Top | |||||
|---|---|---|---|---|---|---|
| Cell-based Target Expression Variations | ||||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: (3S)-4-oxo-4-piperidin-1-ylbutane-1,3-diamine | Ligand Info | |||||
| Structure Description | Human dipeptidil peptidase DPP7 complexed with inhibitor GSK237826A | PDB:3N0T | ||||
| Method | X-ray diffraction | Resolution | 2.45 Å | Mutation | No | [4] |
| PDB Sequence |
DPGFQERFFQ
37 QRLDHFNFER47 FGNKTFPQRF57 LVSDRFWVRG67 EGPIFFYTGN77 EGDVWAFANN 87 SAFVAELAAE97 RGALLVFAEH107 RYYGKSLPFG117 AQSTQRGHTE127 LLTVEQALAD 137 FAELLRALRR147 DLGAQDAPAI157 AFGGSYGGML167 SAYLRMKYPH177 LVAGALAASA 187 PVLAVAGLGD197 SNQFFRDVTA207 DFEGQSPKCT217 QGVREAFRQI227 KDLFLQGAYD 237 TVRWEFGTCQ247 PLSDEKDLTQ257 LFMFARNAFT267 VLAMMDYPYP277 TDFLGPLPAN 287 PVKVGCDRLL297 SEAQRITGLR307 ALAGLVYNAS317 GSEHCYDIYR327 LYHSCADPTG 337 CGTGPDARAW347 DYQACTEINL357 TFASNNVTDM367 FPDLPFTDEL377 RQRYCLDTWG 387 VWPRPDWLLT397 SFWGGDLRAA407 SNIIFSNGNL417 DPWAGGGIRR427 NLSASVIAVT 437 IQGGAHHLDL447 RASHPEDPAS457 VVEARKLEAT467 IIGEWVKAAR477 RE |
|||||
|
|
||||||
| Click to View More Binding Site Information of This Target with Different Ligands | ||||||
| Different Human System Profiles of Target | Top |
|---|---|
|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Human Similarity Proteins
Human Tissue Distribution
|
|
|
There is no similarity protein (E value < 0.005) for this target
|
|
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
| Chemical Structure based Activity Landscape of Target | Top |
|---|---|
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| Target Poor or Non Binders | Top | |||||
|---|---|---|---|---|---|---|
| Target Poor or Non Binders | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Dipeptidyl peptidase II and leukocyte cell death. Biochem Pharmacol. 2006 Jun 28;72(1):70-9. | |||||
| REF 2 | FAP inhibitors. US9346814. | |||||
| REF 3 | Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent. US8470836. | |||||
| REF 4 | Human dipeptidyl peptidase DPP7 | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.